Alimera Sciences (ALIM)
(Delayed Data from NSDQ)
$3.59 USD
+0.08 (2.13%)
Updated Apr 23, 2024 03:59 PM ET
5-Strong Sell of 5 5
D Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
ALIM 3.59 +0.08(2.13%)
Will ALIM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALIM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALIM
New Strong Sell Stocks for March 13th
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
ALIM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novavax (NVAX) Reports Q4 Loss, Lags Revenue Estimates
Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates
Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates
Other News for ALIM
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Alimera (ALIM)
Alimera Sciences initiated with bullish view at Maxim
The top stocks with buying pressure across the Russell universe - Jefferies
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alimera Sciences reports inducement grants under Nasdaq listing rule